188 related articles for article (PubMed ID: 17891346)
1. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.
Takahashi T; Konta T; Takasaki S; Ichikawa K; Takeishi Y; Kubota I
Clin Exp Nephrol; 2007 Sep; 11(3):202-208. PubMed ID: 17891346
[TBL] [Abstract][Full Text] [Related]
2. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.
Lakshmanan AP; Thandavarayan RA; Palaniyandi SS; Sari FR; Meilei H; Giridharan VV; Soetikno V; Suzuki K; Kodama M; Watanabe K
Eur J Pharm Sci; 2011 Dec; 44(5):627-34. PubMed ID: 22033153
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan.
Fan YY; Baba R; Nagai Y; Miyatake A; Hosomi N; Kimura S; Sun GP; Kohno M; Fujita M; Abe Y; Nishiyama A
Hypertens Res; 2006 Mar; 29(3):169-78. PubMed ID: 16755152
[TBL] [Abstract][Full Text] [Related]
4. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production.
Fujimoto S; Satoh M; Horike H; Hatta H; Haruna Y; Kobayashi S; Namikoshi T; Arakawa S; Tomita N; Kashihara N
Hypertens Res; 2008 Feb; 31(2):305-13. PubMed ID: 18360051
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
Igase M; Yokoyama H; Ferrario CM
Ther Adv Cardiovasc Dis; 2011 Dec; 5(6):297-304. PubMed ID: 22089474
[TBL] [Abstract][Full Text] [Related]
7. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.
Kadowaki D; Anraku M; Tasaki Y; Taguchi K; Shimoishi K; Seo H; Hirata S; Maruyama T; Otagiri M
Biol Pharm Bull; 2009 Dec; 32(12):2041-5. PubMed ID: 19952425
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats.
Gounder VK; Arumugam S; Arozal W; Thandavarayan RA; Pitchaimani V; Harima M; Suzuki K; Nomoto M; Watanabe K
Int Immunopharmacol; 2014 Feb; 18(2):282-9. PubMed ID: 24291173
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Sada T; Mizuno M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Mizuno M; Sada T; Kato M; Koike H
Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
[TBL] [Abstract][Full Text] [Related]
11. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.
Nakamoto T; Harasawa H; Akimoto K; Hirata H; Kaneko H; Kaneko N; Sorimachi K
Eur J Pharmacol; 2005 Dec; 528(1-3):43-51. PubMed ID: 16336959
[TBL] [Abstract][Full Text] [Related]
12. Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress.
Shimizu S; Saito M; Oiwa H; Ohmasa F; Tsounapi P; Oikawa R; Dimitriadis F; Martin DT; Satoh I; Kinoshita Y; Tomita S
Neurourol Urodyn; 2014 Mar; 33(3):350-7. PubMed ID: 23775684
[TBL] [Abstract][Full Text] [Related]
13. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
14. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Takai S; Miyazaki M
Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
[TBL] [Abstract][Full Text] [Related]
15. Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein.
Namikoshi T; Tomita N; Satoh M; Haruna Y; Kobayashi S; Komai N; Sasaki T; Kashihara N
Am J Hypertens; 2007 Oct; 20(10):1085-91. PubMed ID: 17903692
[TBL] [Abstract][Full Text] [Related]
16. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Paulis L; Becker ST; Lucht K; Schwengel K; Slavic S; Kaschina E; Thöne-Reineke C; Dahlöf B; Baulmann J; Unger T; Steckelings UM
Hypertension; 2012 Feb; 59(2):485-92. PubMed ID: 22215717
[TBL] [Abstract][Full Text] [Related]
17. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Yoshida K; Kohzuki M
Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
[TBL] [Abstract][Full Text] [Related]
18. AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.
Rodríguez-Iturbe B; Sato T; Quiroz Y; Vaziri ND
Kidney Int; 2004 Aug; 66(2):668-75. PubMed ID: 15253721
[TBL] [Abstract][Full Text] [Related]
19. [Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats].
Ran JM; Lao GC; Xu G; Xie B; Zhang Y; Liu W; Feng Q; Guo J
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1557-61. PubMed ID: 18956640
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan, an angiotensin II receptor blocker inhibits the progression of cataract formation in cadmium chloride induced hypertensive albino rats.
Choudhary R; Bodakhe SH
Life Sci; 2016 Dec; 167():105-112. PubMed ID: 27744053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
